Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy?

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Verrica Pharmaceuticals Inc. despite lower revenues, with a focus on how actual results compare to estimates impacting stock price [1] Earnings Expectations - Verrica Pharmaceuticals is expected to report a quarterly loss of $0.25 per share, reflecting a year-over-year change of +47.9$1.79 million, down 10.1% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst assessments [4] - The Most Accurate Estimate for Verrica is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +4% [10] Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8] - Verrica currently holds a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [11] Historical Performance - In the last reported quarter, Verrica was expected to post a loss of $0.37 per share but actually reported a loss of$0.49, resulting in a surprise of -32.43% [12] - Over the past four quarters, the company has beaten consensus EPS estimates two times [13] Industry Comparison - Xeris Biopharma, another player in the Zacks Medical - Drugs industry, is expected to report earnings per share of $0.07 for the same quarter, indicating a year-over-year change of +30$60.59 million, up 36.5% from the previous year [17]